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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
Introduction
The development of antimicrobial resistance by bacterial pathogens is a global crisis of
increasing importance [1]. Scientists now recognize that each new antibiotic produced has a
limited lifespan and therefore new anti-infective agents are constantly in demand. Throughout
history, cultures have relied heavily on plants for their therapeutic properties. Many of the plants
used in traditional medicine are still in use to this day [2]. Reports have estimated that plants
have contributed to the development of at least half of current pharmaceuticals [3]. However,
few of these are used as antimicrobials, and the vast majority are from bacterial and fungal
sources [2]. This has prompted the scientific community to search for phytochemicals which can
be used to develop pharmacetucal treatments for disease and illness-causing bacterial pathogens.
With an estimated 250,000 to 500,000 plant species on earth, plant based antimicrobials
represent a vast untapped reservoir with great pharmaceutical potential [2]. Furthermore, marine
organisms account for about half of the worlds biodiversity and have been identified as an
invaluable source of bioactive compounds as well. Although numerous marine organisms and
sponges have been found to exhibit antimicrobial behaviour, antimicrobial activity of many
marine organisms has yet to be explored [4]. The isolation and characterization of natural
antimicrobials from plant and marine sources may lead to the development of antimicrobial
agents to help control antimicrobial-resistant pathogens.
Antimicrobial Resistance
Antibiotic therapy is often the initial action taken against microbial infections in humans
although a positive correlation is known to exist between antibiotic use and antimicrobial
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resistance development [5]. Furthermore, the incidence of antimicrobial resistance in foodpoisoning bacteria has also increased, partly due to the excessive use of antibiotic therapy in
healthy livestock [6]. There is significant public demand for reformed prescribing practices by
physicians and the cessation of unnecessary feeding of low levels of antibiotic to healthy foodproducing animals [6]. Although informed physcians have improved prescribing practices,
economic gain represents a strong motivator to farmers to continue to over-use antibiotics.
Resistance in common pathogens has now made some of the most effective and reliable
antimicrobial agents obsolete [1]. Of particular concern are those organisms which have
developed resistance to several classes of antibiotics. Infections which were once easily cured
may now require several courses of antibiotics and treatment may take months or years. In the
past, pharmacetucial coprorations were consistently producing new, more potent antimicrobial
agents in order to compete with the development of antimicrobial resistance. Although the need
for new antimicrobials is apparent, pharmaceutical corporations are no longer developing
sufficient amounts of novel antimicrobials and bacterial strains have developed resistance to
even the newest antibiotics [7]. It is clear that without safe, effective alternatives readily
available, antimicrobial resistance has the potential to hinder our ability to treat serious infections
[5].
Relevant Bacterial Species
There are a number of bacterial species that are currently regarded as high priority
pathogens based on antimicrobial resistance development, high incidence of infection, or a
combination of both. Several bacterial species account for the majority of the cases of food borne
illness and outbreaks. Bacillus subtilis is widespread in the environment, and can cause food
spoilage and food borne illness even after cooking due to its ability to form spores [8].
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Campylobacter jejuni is the leading cause of food borne bacterial gastroenteritis worldwide [9].
Clostridium perfringens food poisoning ranks among the most common foodborne illnesses
worldwide [10]. Escherichia coli 0157 H:7 is responsible for many food and water borne
outbreaks of diarrhea and hemorrhagic colitis worldwide [11]. Listeria Monocytogenes is a
ubiquitous pathogen that is responsible for food borne outbreaks, often affecting
immunocompromised individuals, pregnant women and newborns [12]. Salmonella enterica
serovar typhimurium is a common cause of bacterial enterocolitis. Furthermore, testing has
shown that an increasing proportion of isolates of Salmonella enterica are now resistant to
several antimicrobial agents [13].
There are also a number of bacterial pathogens which contribute to many of the cases of
bacterial infections in humans. Strains of the pathogenic bacteria Acinetobacter baumanii have
been reported to be resistant to all known antibiotics [14]. Clostridium difficile is a bacterial
species often associated with hospital outbreaks, due to the prevalent use of broad-spectrum
antibiotics. One fluoroquinolone-resistant strain has been identified as the cause of numerous
outbreaks of severe C. difficile infection [15]. Carbapenem

reisitant strains of Klebsiella

pneumoniae; a major cause of nosocomial infections, have left few treatment options for the
infection [16]. Treatment of infections caused by the pathogenic bacteria Pseudomonas
Aeruginosa is becoming more difficult due to its rapidly developing resistance to multiple
classes of antibiotics [17]. Methycillin-resistant Staphylococcus areus (MRSA) infections are a
major cause of hospital-acquired infections, and is now considered an epidemic in many US
hospitals and long term care facilities [18]. Streptococcus pneumoniae is a human pathogen
currently exhibiting fluoroquinolone resistance and representing a major cause of morbidity and
mortality worldwide via diseases such as pneumonia, meningitis, and bacteraemia [19]. These

4
twelve bacterial species pose a significant risk to the public and intervention is currently required
to regain control over these common pathogens.
Natural Products in Drug Discovery
With the increase in bacterial resistance to conventional treatments, there is also an
increasing interest in plant-derived antimicrobial compounds. The screening of natural sources
has been key in the discovery of many classes of drugs. Natural products, including both extracts
as well as pure compounds have unlimited potential as new drug leads due to their tremendous
chemical diversity [20]. Plant and marine sources have been found to be a limitless source of
bioactive compounds [4]. The distribution of plant compounds is commonplace in natural food
stores, and consumer demand for alternative treatments is increasing [2]. There was a reported
37% increase in the sale of plant derived medicines between the years 1995 to 1996 [21].
Unfortunately, the purity of these substances is unreliable and there is limited information
available regarding dosage. Many scientists believe that natural antimicrobials may eventually
replace traditional approaches of controlling pathogens [22]. The reasons to further develop
natural products are numerous and include the high cost of currently available synthetic
medicines, adverse side-effects of pharmaceuticals, and the public perception of gentleness of
natural medicines.
The traditional method of compound isolation and characterization has long been used
by pharmaceutical companies for natural product development. However, the process eventually
acquired as reputation for being expensive, repetitive, tedious, and time consuming, causing
pharmaceutical companies to draw back on these research approaches in the 1990’s and early
2000’s. At this time a new method was developed which relied on combinatorial chemistry and
large compound libraries. The success of this method has been limited, which is proven by the
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fact that only one combinatorial new entity has been approved by the FDA since the 1980’s [23].
The public has relied on plants for new lead compounds in the initial stages of pharmaceutical
development, and the combinatorial chemistry approach has not yet shown to be productive. It is
unclear as to whether or not pharmaceutical companies and researchers will revert to the
traditional method of isolation and characterization to increase the amount of new
pharmaceuticals introduced to the market. It is important to note, however, that there have been
numerous technological advances making the traditional method a more viable option. These
include more sensitive instruments and more available NMR/MS data.
Natural Products as Antimicrobials
Natural products have been significant in antibiotic drug discovery with most antibiotics
being derived from a natural product or a natural product lead [24]. Reports estimate that 60% of
commercially available anti-infective agents are of natural product origin [3, 25]. Plants produce
both primary and secondary metabolites. Those metabolites responsible for their defense
mechanism fall under the latter category. Secondary metabolites are produced by plants for the
purpose of protection against predators as well as infections [26]. Secondary metabolites such as
phenolics, terpenoids, alkaloids, and flavonoids have known antimicrobial properties [2].
Similarly, marine sponges have developed chemical defenses to protect against the colonization
of pathogenic bacteria [27]. For this reason, the antimicrobial activity of marine sponges has
been studied in an attempt to harness the sponges natural potency [28-30]. Marine sources have
been found to be an invaluable source of bioactive compounds [4].

6
Natural Products in Food Safety
Characterization of bioactive properties of plant extracts has potential application, not
only in pharmaceuticals, but in agriculture and food preservation as well [31-33]. Currently, the
most common application of natural antimicrobials is the direct addition of antimicrobial
compounds to food [34]. Microorganisms can cause off flavor, odor, color, sensory, and textural
properties in foods. Furthermore, microorganisms in food can cause food-borne illness [35].
Consumer concern regarding synthetic chemical additives has made foods preserved with natural
additives the more popular choice [34]. For this reason, scientists have expanded their efforts to
discover natural compounds that can prevent or inhibit the growth of microorganisms in food.
Some natural antimicrobials are now used industrially in the processing of food. Foods are often
dipped, sprayed, or coated with active solutions prior to packaging. This type of application of
natural antimicrobial compounds is now utilized on a variety of foods including meat, fish, dairy
products, minimally processed fruit and vegetables, and cereal-based products [34].
In this study, the antimicrobial activity of a number of plant and marine extracts is
investigated. A number of extracts are chosen and the active compound(s) isolated and
identified. The compounds are thoroughly investigated using a variety of techniques intended to
evaluate each compound’s antimicrobial activity level, stability, safety, and overall potential for
use as a natural antimicrobial.
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CHAPTER 2: ISOLATION AND IDENTIFICATION OF COMPOUNDS FROM
PLANTAND MARINE ORGANISMS WITH ANTIMICROBIAL ACTIVITY
Screening of Plant and Marine Organisms
Introduction
The natural products repository of the National Cancer Institute (NCI) through the U.S.
National Institutes of Health (NIH) has collected close to 17,000 extracts of plant and marine
organisms. Extracts were provided by the National Cancer Institute (NCI) to allow for this
research to take place. Initial screening of antibacterial compounds from plants is commonly
performed on crude extracts in order to identify ‘hits’, which are selected based on their desired
bioactivity. In order to identify antimicrobial agents, the most commonly used screening method
is known as broth microdilution [36]. This method allows for the testing of multiple samples at
once. Although the this method is used numerous times throughout this work, at the initial
screening stage, the method was simplified in order to test hundreds of plant and marine extracts
at a single concentration, which could be repeated to test a number of different bacterial species.
Materials and Methods
Bacterial species- Seven high priority pathogens were used to fulfill this aim. Bacterial
reference strains were obtained from the American Type Culture Collections (ATCC,
Mannassas, VA). The bacterial strains included were: A. baumannii, ATCC 19606; C. jejuni,
ATCC 33291; C. difficile, ATCC 9689; C. Perfringens, ATCC 13124; K. pneumoniae, ATCC
13883; S. pneumoniae, ATCC 49136; and P. Aeruginosa, ATCC 27853.
Plant and marine extracts- A total of 106 extracts of plant and marine organisms
obtained from the natural products repository of NCI were identified through preliminary
experiments on thousands of extracts which were chosen based on their inhibitory activity on E.
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coli 0157 H:7 bacteria. Each extract was prepared by the Natural Products Extraction Laboratory
by extracting each organism with a 1:1 mixture of dichloromethane and methanol and then with
water. Each extract was stored at -20 ˚C.
Antimicrobial screening- A simplified version of the broth microdilution method
described by the Clincal and Laboratory Standards Institute (CLSI) guidelines was utilized for
the purpose of screening the extracts [37, 38]. Brain heart infusion broth (BHI), thioglycollate
broth, nutrient broth, and cation-adjusted mueller hinton broth (CAMHB) were used for the
growth medium. Each plant extract, was dissolved in dimethyl sulfoxide (DMSO) to produce a
stock solution with the concentration of 1 mg/ml. This was further diluted in sterile distilled
water to prepare test solutions with a concentration of 50 µg/ml. Overnight bacterial broth
suspension was diluted 20x in an appropriate broth. Assay plates were prepared to contain
extracts at a single concentration; A. baumannii; 10 µg/ml, C. jejuni; 5 µg/ml, C. difficile 5
µg/ml; C. Perfringens; 5 µg/ml, K. pneumoniae; 5 µg/ml, S. pneumoniae; 5 µg/ml, and P.
Aeruginosa; 20 µg/ml.

Assay plates were incubated in appropriate conditions (aerobic,

anaerobic, or microaerophilic) at 37 ºC for 24 h, and growth or no-growth was assessed by the
naked eye through comparison with controls. DMSO dilutions in sterile distilled water (1:19
ratio DMSO to water) that did not contain any test material and a blank containing no bacteria
were included as controls.
Results
Screening of 106 plant and marine organism extracts led to the identification of 4
extracts with superior antimicrobial activity. The majority of the extracts tested had limited
antimicrobial activity; inhibiting the growth of only one or none of the tested microorganisms.
The extracts showing the greatest antimicrobial activity inhibited the growth of a minimum of 3
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bacterial species. These extracts were N014267 from Mammea africana, C025163 from
Phyllospongia papyracea, C022687 from Monanchora unguiculata, and C022615 from Dysidea
herbacea (Tables 1a-c). These 4 extracts demonstrated activity against a broad spectrum of
bacterial species. The M. africana extract inhibited the growth of C. difficile, C. jejuni, and S.
Pneumonoiae at a concentration of 5 µg/ml. The P. papyracea extract also inhibited the growth
of C. difficile, C. jejuni, and S. Pneumonoiae at a concentration of 5 µg/ml. Monanchora
unguiculata is especially noteworthy as this extract showed inhibitory activity on every bacterial
species included in the screening. Furthermore the M. unguiculata extract was the only extract of
the 106 initial extracts to exhibit inhibitory activity on the bacterial species A. baumani and P.
aeruginosa. Finally, the D. herbacea extract inhibited the growth of C. difficile, C. jejuni, C.
perfringens, and S. pneumoniae at a concentration of 5 µg/ml. Based on the results of the initial
screening, these 4 extracts were chosen for further study as they showed the strongest, broadspectrum antimicrobial activity.
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Table 1a Antimicrobial activity of extracts numbered 1-40 on bacterial species.

+ Represents inhibition of bacterial growth at the specified concentration by comparison of
turbidity with a Blank assessed by the naked eye following 24 hr incubation period.
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Table 1b Antimicrobial activity of extracts numbered 41-80 on bacterial species.

+ Represents inhibition of bacterial growth at the specified concentration by comparison of
turbidity with a Blank assessed by the naked eye following 24 hr incubation period.
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Table 1c Antimicrobial activity of extracts numbered 81-106 on bacterial species.

+ Represents inhibition of bacterial growth at the specified concentration by comparison of
turbidity with a Blank assessed by the naked eye following 24 hr incubation period.

13
Discussion
The first extract chosen for its significant inhibitory activity was from Mammea
africana. M. africana (Family Clusiaceae) is widely distributed in tropical Africa. The stem bark
of the plant is commonly used in traditional medicine for the treatment of malaria related fever,
internal heat, microbial infections, stomach pains, scabies and other skin diseases, rheumatic pain
and fybromyoma [39-41]. Mammea coumarins have been isolated and identified from a variety
of plant species including Mammea africana and other species of Mammea, Mesua, and
Calophyllum [33]. Mammea coumarins have been found to express a wide range of bioactivities,
including antibacterial [42, 43], antifungal [44], antioxidant [45], insecticidal [46], anticancer
[39, 45, 47], and anti-HIV [48].
A second extract which was identified through screening was from Phyllospongia
Papyracea. P. Papyracea ( Family Thorectidae) is a marine sponge of the Dictyoceratida order.
Two types of molecular structures have been recorded as discovered from Phyllospongia,
scalarane sesterpenes and polybrominated biphenyl ethers [49]. While much research has been
conducted on the former, the bioactivity of the latter is less well known [49]. Bromophenolic
compounds are present in high concentrations in marine sponges and have been found to show
antibacterial [50], antifungal [51], and anti-inflammatory activities [52] as well as cytotoxicity
[25, 50, 53].
The extract from Monanchora unguiculata was chosen as it was shown to possess
inhibitory activity on all of the bacterial species included in the screening. M. unguiculata
(Family Crambeidae) is a marine sponge with distribution in the Indian Ocean. Investigation of
the sponge M. unguiculata has previously led to the identification of pentacyclic guanidine
alkaloids [54]. The cyclic guanidine derivatives have previously been shown to possess a broad
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range of bioactivity. This class of metabolites has shown antifungal, antiviral, antiprotozoal, and
antimicrobial activities. Furthermore, these compounds have also been found to exhibit
cytotoxic, antimalarial, and anti-HIV activity [55, 56]. The guanidine alkaloids group includes
ptilomycin A, the cramescins, crambescidins, ptilocaulins, mirabilines, and the batzelladines,
which have similar structural features and biological activities. The members of this class include
the

pentacyclic

and

tricyclic

guanidine

alkaloids

which

bear

the

(5,6,8b)-

triazaperhydroacenaphthalene skeleton [57]. Increasing interest in this group of compounds has
led researchers to begin studies to synthesize such compounds [58].
The final extract that was chosen for further study was obtained from the sponge
Dysidea herbacea (Family Dysideidae). D. herbacea is a tropical marine sponge which has been
collected from the waters off the shore of Australia and Indonesia [59]. This sponge has two
known chemotypes. The first produces sesquiterpenes and polychlorinated amino acid
derivatives, while the other produces only polybrominated diphenyl ethers [60]. It has been
suggested that the production of polybrominated diphenyl ethers is due to a cyanobacterium,
Oscillatoria spongeliae, and not the sponge itself. The compounds are thought to offer a mode of
protection to the sponge from predators and bacterial invasion [61]. The polybrominated
diphenyl ethers have been found to exhibit a range of notable activities. They have been found to
exhibit antibacterial activities on S. aureus and T. Mentagrophytes, as well as inhibition of a
number of tumor-promoting enzymes [60, 62].
Previous work pertaining to these four species is far from complete. Although it is
known that they all possess bioactive compounds, none of these species has previously been
tested for antimicrobial activity on a broad range of bacterial pathogens.

15
Isolation of Active Compounds
Introduction
Natural product research often follows a number of steps intended to best utilize the
biologically active compounds of plant resources. These steps are extraction, pharmacological
screening, isolation and characterization of bioactive compounds, toxicological evaluation, and
finally clinical evaluation. [63]. There are numerous potential setbacks involved in this type of
research. Fractionation of extracts can lead to a reduction or loss of biological activity by
compound break-down or loss of additive or synergistic effects between other active compounds
present in the extract. Furthermore, there is no one standardized separation technique for extracts
and when an active compound is isolated, it is often not possible to re-isolate even when
following an identical protocol [20]. In this regard, a systematic approach to extraction and
isolation of compounds was of the utmost importance in obtaining pure antimicrobial
compounds.
Each extract is a complex combination of bioactive compounds and phytochemicals with
different characteristics. For this reason, separation poses a challenge, often involving numerous
steps and a variety of fractionation techniques [63]. Bioassay is necessary between each step to
identify the active fraction/fractions. When an active fraction was identified, a separation plan
was made based on the characteristics of the compounds which were deduced from the previous
separation, ex. polarity, size of molecule, etc.
Materials and Methods
Isolation of Active Compounds - Each extract was fractionated individually as described
in the following paragraphs. A combination of multiple purification techniques including liquidliquid extraction, open column chromatography, Sephadex cartridge, high performance liquid
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chromatography (HPLC) was utilized. Solvents were removed using evaporation or sublimation,
to determine the final amount obtained for each sample. Samples were dissolved and diluted to
100 µg/ml in an appropriate solvent. A bioassay guided approach to fractionation was taken; in
which, the activity of fractions was assessed at each stage of fractionation via the simplified
microbroth dilution method previously described using a bacterial strain proven to be inhibited
by the extract in the screening. Fractions showing inhibitory activity were subject to additional
fractionation. Thin layer chromatography (TLC) and high performance liquid chromatography
(HPLC) were used to determine the point in the separation process when a single pure active
compound has been isolated.
Fractionation and isolation of compound 1 from Mammea africana - Crude extract from
the bark of the M. africana was partitioned by liquid-liquid extraction using hexane, ethyl
acetate, butanol, and water. Active fractions were identified through an antibacterial activity
assay. The assay revealed the hexane and ethyl acetate fractions exhibited antimicrobial activity.
These two fractions were combined and subjected to fractionation via open column
chromatography. The chromatography was carried out on 100 g of silica gel (40-60 μm, Acros,
NJ) in a glass column (457×40 mm) and eluted with hexane, acetone, and methanol to yield a
total of 13 fractions. Fraction 5 and 6 were identified as containing the active compound. HPLC
with a reversed-phase C-18 column (150 x 4.6 mm) by a Hitachi DAD L-2455 detector was used
to verify that a single compound was present in Fraction 5 (Scheme 1).
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Scheme 1 Flow chart depicting the bioactivity-driven fractionation of Mammea africana extract.
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Fractionation and isolation of compound 2 from Phyllospongia papyracea - Crude
extract from P. papyracea was partitioned by liquid-liquid extraction using hexane, ethyl acetate,
n-butanol, and sterile distilled water. Bioactivity assay revealed the hexane and ethyl acetate
fractions exhibited antimicrobial activity. These two fractions were combined and subjected to
fractionation via open column chromatography. The chromatography was carried out on 100 g of
silica gel (40-60 μm, Acros, NJ) in a glass column (457×40 mm) and eluted with hexane,
acetone, and methanol to yield a total of 15 fractions. Fractions were monitored on TLC Silica
Gel 60 F254 (EMD, Gibbstown, NJ) and visualized under UV (254 nm and 365 nm) and 10%
H2SO4 (in EtOH). Fraction 3,4 and 5 were identified as active fractions and were analyzed with
high performance liquid chromatography (HPLC) on a reverse phase C18 column (150 x 4.6
mm) by a Hitachi DAD L-2455 detector to determine whether a single compound was present.
UV-VIS spectrum was recorded in methanol/H2O using a Hitachi DAD L-2455 (Scheme 2).
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Scheme 2 Flow chart depicting the bioactivity-driven fractionation of Phylospongia papyracea
extract.
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Fractionation and isolation of compound 3 from Monanchora unguiculata - Crude
extract from M. unguiculata was partitioned by liquid-liquid extraction using ethyl acetate,
butanol, and water. Active fractions were identified through an antibacterial activity assay. The
assay revealed the butanol fraction exhibited antimicrobial activity. This fraction was subjected
to fractionation via XAD column chromatography using the solvents water, ethanol, and finally
acetone. Following bioassay, the ethanol fraction was found to contain the active compound.
This fraction was further separated using OASIS cartridge chromatography and sterile distilled
water as the solvent. Fraction 2-2 was found to be active, and HPLC was used to further purify
the fraction using a reversed-phase C-18 column (150 x 4.6 mm) by a Hitachi DAD L-2455
detector. The first peak was collected and was analysed using HPLC to determine that it
contained a purified substance (Scheme 3).
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Scheme 3 Flow chart depicting the bioactivity-driven fractionation of Monanchora unguiculata
extract.
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Fractionation and isolation of compound 4 from Dysidea herbacea - Crude methanol
extract from D. herbacea was partitioned via open column chromatography. The
chromatography was carried out on 100 g of silica gel (40-60 μm, Acros, NJ) in a glass column
(457×40 mm) and eluted with hexane, acetone, and methanol to yield a total of 12 fractions.
Fraction 2 was identified via bioassay to contain the active fraction. It was filtered using
Whatman No. 2 filter paper to separate the precipitate. The precipitate was then subjected to a
Sephadex column. The first fraction to elute was active. HPLC was used to further purify the
fraction using a reversed phase C-18 column (150 x 4.6 mm) by a Hitachi DAD L-2455 detector.
The second peak was collected and was analysed using HPLC to determine that it contained a
purified substance (Scheme 4).
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Scheme 4 Flow chart depicting the bioactivity-driven fractionation of Dysidea herbacea extract.
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Results
Extracts were fractionated individually as described following the outline depicted in
Schemes 1-4. Each time a sample was fractionated; all fractions were included in a simplified
microbroth dilution assay to identify the active fraction or fractions. In this way, the active
fraction was purified as the inactive fractions were removed. HPLC was used to determine the
presence of a single compound. If a fraction led to an HPLC chromatogram displaying a single
peak, fractionation was discontinued and further identification was initiated (Figure 1-4). The
chromatograms obtained through HPLC analysis of the isolated product from the four active
extracts each display a prominent single peak. The final fractions, assumed to be single
compounds, were named as follows: Compound 1, isolated from crude M. africana extract,
Compound 2, isolated from crude P. papyracea extract, Compound 3 isolated from crude M.
unguiculata extract, and Compound 4, isolated from crude D. herbacea extract.
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Figure 1 HPLC chromatogram of compound 1 isolated from Mammea africana using a 90%
methanol isocratic method.
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Figure 2 HPLC chromatogram of compound 2 isolated from Phyllospongia papyracea using an
isocratic 90% methanol method.
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Figure 3 HPLC Chromatogram of compound 3 isolated from Monanchora unguiculata using an
isocratic 100% methanol method.
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Figure 4 HPLC chromatogram of compound 4 isolated from Dysidea herbacea using an
isocratic 100% methanol method.
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Discussion
The goal of fractionation is to isolate the active compound in the extract by
systematically removing the components which do not contribute to its bioactivity of interest.
HPLC is often the final analytical tool used. In this case, active fractions which were believed to
contain a single compound were analyzed by reversed-phase HPLC using an isocratic methanolbased method. A single peak is observed when a compound passes through the detector and
absorbs UV light. When the HPLC chromatogram displayed a single peak, fractionation was
discontinued and characterization studies were initiated. In this case, a single peak in an HPLC
chromatogram was the signal that the active compound had been isolated. Figure 3 shows a
number of peaks with retention time under 3 minutes. It is common to see a number of peaks
appear on the chromatogram within the first 5 minutes and these peaks are usually associated
with solvent being detected and are not necessarily attributed to multiple compounds present in
the system being analyzed.
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Identification of Active Compounds
Introduction
Combinatorial chemistry is often employed in determination of chemical identity and
molecular formulae of unknown compounds. Confirmation relies on verification of information
by comparison of liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic
resonance (NMR) data. Integration of MS and NMR spectral data is the method of choice for
structure verification [64].
Materials and Methods
Characterization of Active Compounds - Nuclear magnetic resonance spectroscopy
(NMR) in combination with mass spectrometry (MS) was performed in the Chemistry
Department at Wayne State University. Chromatograms were analyzed by the post-doctoral
researcher, Dr. Sun. Through analysis of chromatograms and comparison with data previously
reported in the literature, the chemical structure of the compounds was determined.
Characterization of compound 1 from Mammea africana - The compound was analyzed on a
Waters LCT Premier high resolution exact mass spectrometer and Waters ZQ2000 single
quadrupole mass spectrometer (Waters Corp., Milford, Massachusetts). NMR spectra (1H,

13

C,

DEPT) were recorded on a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto,
California). 1H and

13

C were observed at 400.13 and 100.03 MHz using DMSO-d6 as the

solvent.
Characterization of compound 2 from Phyllospongia papyracea: The compound was
analyzed on a Waters LCT Premier high resolution exact mass spectrometer (Waters Corp.,
Milford, Massachusetts).

The mass spectrometer was operated in negative electrospray

ionization at a temperature of 350º C and a voltage of 4 kV. Mass scan spectra were measured
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from 100 m/z up to 1400 m/z at 1000 amu/second. NMR spectra (1H, 13C, DEPT) were recorded
on a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto, California). NMR spectra (1H
and 13C) were observed at 400.13 and 100.03 MHz using DMSO-d6 as the solvent. Mass spectra
were obtained on a QSTAR XL MS/MS system.
Characterization of compound 3 from Monanchora unguiculata: NMR spectra were
obtained with Varian VNMRS-500 MHz (500 MHz, 1H;125 MHz,
MHz (600 MHz, 1H;150 MHz,

13

13

C) and Agilent DD2-600

C) spectrometers; chemical shifts (δ) are reported in ppm

referenced to the solvent peak. The compound was analyzed on a Waters LCT Premier high
resolution exact mass spectrometer (Waters Corp., Milford, Massachusetts), EIMS on a VG 70250-S mass spectrometer (Micromass Corp., Manchester UK) . Optical rotations were taken on a
Perkin-Elmer 341 polarimeter.
Characterization of compound 4 from Dysidea herbacea: The compound was analyzed
on a Waters LCT Premier high resolution exact mass spectrometer and Waters ZQ2000 single
quadrupole mass spectrometer (Waters Corp., Milford, Massachusetts). NMR spectra (1H,

13

C,

DEPT) were recorded on a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto,
California). 1H and

13

C were observed at 400.13 and 100.03 MHz using DMSO-d6 as the

solvent.
Results
Characterization of compound 1 from Mammea africana - Fractionation of the
traditional medicinal plant Mammea africana yielded a known coumarin with antimicrobial
activity. The active compound, appearing as yellow crystals was analyzed using 1H and

13

C

NMR (Table 2). Its 1H NMR spectrum showed one olefinic proton singlet at 5.93 characteristic
of H-3 of a 4-substituted coumarin. 1H NMR spectrum δ 7.39 (2H, dd, J=7.0, 3.5 Hz), 7.52 (2H,
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dd, J=7.0, 3.5 Hz), and 7.51 (1H, t, J=7.0 Hz), and 13C NMR spectrum 137.21, 127.39, 129.14,
and 129.72 indicated the presence of one phenyl group. δ 3.55 (2H, d, J=8.0 Hz), 5.26 (1H, t,
J=8.0 Hz), 1.86 (3H, s), and 1.74 (3H, s) and δ 21.65, 120.59, 135.4, 25.8, and 18.0 showed onesubstituted prenyl group. δ2.85 (1H, d, J=8.0), 2.17 (1H, m), 0.89 (6H, d, J=8.0Hz) and δ207.1,
53.6, 24.7, 22.7, and 22.7 indicated the presence of one isovaleryl group. Two phenolic hydroxyl
signals were at δ 11.0 and 9.9 in 1H NMR, too. Comparison of its 1H and 13C NMR spectra with
those previously reported in the literature allowed this active compound to be identified as
mammea A/AA [65]. The structure of mammea A/AA is illustrated in (Figure 5).
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Table 2 1H and 13C NMR spectral data of compound 1 isolated from Mammea africana.
Position

δC

δH

2

159.5 s

3

112.7 d

4

154.4 s

4a

100.8 s

5

159.5 s

6

107.2 s

7

163.2 s

8

108.0

8a

156.6 s

1'

137.2 s

2', 6'

127.4d

7.39, dd, J=3.5, 7.0

3', 5'

129.1 d

7.52, dd, J=3.5, 7.0

4'

129.7 d

7.51, t, J=7.0

1''

207.1 s

2''

53.6 t

2.85, d, J=8.0

3''

24.7 d

2.17, m

4'', 5''

22.7q

0.89, d, J=8.0

1'''

21.7t

3.55, d, J=8.0

2'''

120.6d

5.26, t, J=8.0

3'''

135.4 s

4'''

25.8 q

1.86, s

5'''

18.0 q

1.74, s

5.931, s
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Figure 5 Chemical structure of compound 1; Mammea A/AA isolated from Mammea africana.

The structure of the active compound was determined to be 4-phenyl-5,7-dihydroxy-6-(3methylbutanoyl)-8-(3-methyl-2-butenyl)-2H-1-benzopyran-2-one, known as mammea A/AA.
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Characterization of compound 2 isolated from Phyllospongia papyracea - Fractionation
of the sponge Pyllospongia papyracea yielded a known tetrabrominated diphenyl ether with
antimicrobial activity. The active compound, appearing as a white powder was analyzed using
1

H and

13

C NMR.

The compound was identified as 4,6-Dibromo-2-(4,6-dibromo-2-

hydroxyphenol) anisole (CAS80246-35-1) (Figure 10). 1H NMR (CDCl3, 400 MHz) δ 7.34 (d,
J= 2.4Hz, H-5′), 7.43(d, J= 2.4Hz, H-5), 7.17(d, J= 2.4Hz, H-3′), 6.77 (d, J= 2.4Hz, H-3), 4.03 (s,
OCH3);

13

C NMR (CDCl3, 125.7 MHz) δ 150.9 (C-2), 150.4 (C-2′), 145.6 (C-1), 138.7 (C-1′),

130.4 (C-5), 127.4 (C-5'), 120.2 (C-3'), 119.9 (C-4'), 119.0 (C-6), 118.5 (C-3), 117.4 (C-4), 117.3
(C-6′), 61.6 (OCH3); ESIMS [M - H]- m/z 526.712 (15), 528.7144 (83), 530.7039 (100),
532.7091 (77), 534.7084 (20), 534.7549 (5). These spectral data were in agreement with those
previously reported in the literature [53, 66].
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Table 3 1H and 13C NMR spectral data of compound 2 isolated from Phyllospongia papyracea.
Position
1
2
3
4
5
6
1′
2′
3′
4′
5′
6′
OCH3

1

H

6.77 (d, J= 2.4, H-3),
7.43(d, J= 2.4, H-5),

7.17(d, J= 2.4, H-3′),
7.34 (d, J= 2.4, H-5′),
4.03 (s)

13

C
145.6
150.9
118.5
117.4
130.4
119.0
138.7
150.4
120.2
119.9
127.4
117.3
61.6
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Figure 6 Chemical structure of compound 2; a tetrabominated diphenyl ether isolated from
Phyllospongia papyracea.

OH

OCH3
O

Br

Br

Br
Br

The structure of the active compound was determined to be Phenol, 3,5-dibromo-2-(3,5dibromo-2-methoxyphenoxy).
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Characterization of compound 3 isolated from Monanchora unguiculata – Semipreparative HPLC was used to separate chromatographic peaks. One sample collected was found
to exhibit antimicrobial activity. The sample appeared as a light yellow glue. Although this
appeared as a single chromatographic peak, and was believed to be a pure compound, compound 3
actually contains a mixture of compounds. Through comparison of 1H and

13

C NMR data with

those reported in the literature regarding similar marine species, it was found that the sample
exhibited the same ‘vessel’ part system and relative stereochemistry as crambescidin 800,
ptilomycalin A, and fromianmycalin [67-70]. Further analysis of 1H,

13

C NMR data established

that a spermidine residue was present, as the ‘anchor’ however, the exact structure could not be
differentiated. By analysis of DEPT, COSY, TOCSY, HSQC, and HMBC, one of spermidine
residues was the same as fromianmycalin [69]; one of as crambescidin 800 [67]; another as
ptilomycalin A [67, 68], however, the hydroxyl group could not be assigned.
The compound mixture appeared as a light yellow oil, [α]20D 0° (c 0.21, MeOH); UV
(MeOH/water) λmax 248nm; HRESIMS m/z 801.6217 [M+H]+ 401.8152 [M+2]/2 (calcd for C45H81
N6O6, 801.6218, monanchocidin F and crambescidin 800); 392.8095 [M+2]/2 (calcd for C45H79
N6O5, 783.6112, fromianmycalin) ; EIMS m/z 782.9 (1.2), 709.8 (2.2), 683.8 (4.3), 643 (3.3),
613.7 (2.8), 574.7 (6.6), 544.6 (4.8), 503.3 (8.2), 429.3 (14.9), 402.4 (11.3), 360.4 (12.8), 359.4
(23.5), 358.4 (23.7), 330.4 (27.3), 312.4 (24.7), 311.5 (24.2), 288.3 (23.9), 262.3 (31.1), 261.3
(26.6), 192.2 (33.1), 191.2 (33.7), 149.2 (29.6),113.2 (25.1), 111.2 (25.8), 98.2 (31.1), 99.2 (28.2),
36.0 (100).
In HRESIMS spectrum, a pseudomolecular ion, [M+H], at m/z 801.6217, and two
[M+2]/2 ion peak groups at m/z 401.3131, 401.8152, 402.3191, and 402.8218; 392.3080,
392.8095, 393.3137, and 393.8580, were assigned the molecular formula C45H80N6O6 and
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C45H79N6O5, respectively. EIMS data presented the fragmentation ion at m/z 729 (M-71) and 613
(M-187) from M ion (m/z 800), corresponding to the losses of C4H9N and C9H21N3O,
respectively, which showed the existence of ptilomycalin A’s spermidine residue again. The
position of hydroxyl group was assigned at C-33 depending on the one pair of ion at m/z 574/326
and 544/356 (scheme 5). The configuration of C-33 can not be determined based on the results of
the application of the Mosher’s method because Δδ of C-32 and 34 showed the same positive
value. And the optical value was 0°. This was identified as one new compound, a polycyclic
guanidine alkaloid, monanchocidin F (Figure 7), the NMR data were assigned as Table 3
dependent on 2D NMR as well as two known compounds crambescidin 800 and fromianmycalin
(Figure 8).
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Tabel 4. 1H and 13C NMR data for compound mixture in compound 3 (in CD3OD,)
Monanchocidin F
1

H NMR

1
2a
2b
3
4
5
6a
6b
7a
7b
8
9a
9b
10
11a
11b
12a
12b
13
14
15
16a
16b
17a
17b
18a
18b
19
20
21
22
23
24
25
26
27
28-31
32
33
34
35
36
37
38

0.86, t, 7.8Hz
1.45, m
1.51, m
4.40, br d, 12.0 Hz
5.49, br d, 12.0 Hz
5.68, br t, 12.0 Hz
2.13, m
2.35, m
1.94, m
2.38, m

1

H NMR

Crambescidin 800
1

H NMR

0.86, t, 7.8Hz
0.86, t, 7.8Hz
1.45, m
1.45, m
1.51, m
1.51, m
4.40, br d, 12.0 Hz 4.40, br d, 12.0 Hz
5.49, br d, 12.0 Hz 5.49, br d, 12.0 Hz
5.68, br t, 12.0 Hz 5.68, br t, 12.0 Hz
2.13, m
2.13, m
2.35, m
2.35, m
1.94, m
1.94, m
2.38, m
2.38, m

1.40, t, 12.0 Hz
1.40, t, 12.0 Hz
1.40, t, 12.0 Hz
2.62, dd, 15.6, 6.0 Hz 2.62, dd, 15.6, 6.0 2.62, dd, 15.6, 6.0
Hz
Hz
4.04, m
4.04, m
4.04, m
1.68, m
1.68, m
1.68, m
2.24, m
2.24, m
2.24, m
1.65, m
1.65, m
1.65, m
2.26, m
2.26, m
2.26, m
4.33, m
4.33, m
4.33, m
3.06, d, 6.0
3.06, d, 6.0
3.06, d, 6.0
1.52, m
1.52, m
1.52, m
1.80, m
1.80, m
1.80, m
1.79, m
1.79, m
1.79, m
1.91, m
1.91, m
1.91, m
1.75, m
1.75, m
1.75, m
1.92, m
1.92, m
1.92, m
3.84, br dd, 12.6, 6.0 3.84, br dd, 12.6, 6.03.84, br dd, 12.6, 6.0
Hz
Hz
Hz
1.07, d, 7.2 Hz
1.07, d, 7.2 Hz
1.07, d, 7.2 Hz

4.11, t, 7.2 Hz
1.63, m
1.29, m
1.29, m
1.29, m
1.29, m
1.69
4.03, m
1.40
1.29
1.80, m
2.48, m

4.11, t, 7.2 Hz
1.63, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.80, m
2.48, m

4.13, t, 7.2 Hz
1.97
4.03
1.41
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.80, m
2.48, m

13

C NMR
9.42
26.17
72.3
132.93
129.88
23.01
38.17
83.64
37.86

54.10
30.12
28.19
52.55
49.34
80.68
32.73
18.04
32.55
68.40
20.40
150.1
168.71
68.55
39.93
67.04
37.86
28.84-30.12
28.84-30.12
28.84-30.12
28.84-30.12
28.84-30.12
28.84-30.12
27.67
32.76
166.36

Fromianmycalin
1

H NMR

0.86, t, 7.8Hz
1.45, m
1.51, m
4.40, br d, 12.0 Hz
5.49, br d, 12.0 Hz
5.68, br t, 12.0 Hz
2.13, m
2.35, m
1.94, m
2.38, m
1.40, t, 12.0 Hz
2.62, dd, 15.6, 6.0
Hz
4.04, m
1.68, m
2.24, m
1.65, m
2.26, m
4.33, m
3.06, d, 6.0
1.52, m
1.80, m
1.79, m
1.91, m
1.75, m
1.92, m
3.84, br dd, 12.6, 6.0
Hz
1.07, d, 7.2 Hz

4.11, t, 7.2 Hz
1.63, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.29, m
1.80, m
2.48, m

13

C NMR
9.42
26.17
72.3
132.93
129.88
23.01
38.17
83.64
37.86

54.10
30.12
28.19
52.55
49.34
80.68
32.73
18.04
32.55
68.40
20.40
150.1
168.71
68.55
39.93
67.04
37.86
28.84-30.12
28.84-30.12
28.84-30.12
28.84-30.12
28.84-30.12
28.84-30.12
27.67
32.76
166.36

41
39a
39b
40
41

3.37, m
3.62, m
1.92, m
2.88, m

3.38, m
3.64, m
1.92, m
2.88, m

42a
42b
43a
43b
44

3.51, m
3.63, m
1.95 m
2.05 m
1.65, m
1.75, m
3.12, m

45

47.84

3.32
3.46
3.95, m

3.38, m
3.56, m
2.07, m
3.38, m
3.53, m
3.41, m
3.69, m
4.03, m

1.75
1.93
3.12, m

1.75
1.93
3.12, m

32.87

19.86
39.94
58.51
69.38

38.52

3.38, m
3.64, m
1.92, m
2.88, m

47.84

3.32
3.46
3.95, m

58.51

1.75
1.93
3.12, m

32.87

19.86
39.94

69.38

38.52
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Figure 7 Chemical structure of a component of compound 3; monanchocidin F isolated from
Monanchora unguiculata
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The mixture of compounds was determined to include the new compound monanchocidin F,
where R1=OH, R2=H.
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Figure 8 Chemical structure of components of compound 3; the compounds cambescidin and
fromianmycalin, isolated from Monanchora unguiculata.
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The mixture of compounds was determined to include the known compounds crambescidin 800,
where R1=H, and fromainmycalin, where R2= OH.
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Scheme 5 Characterization of new compound monanchocidin F by MS fragmentation (m/z
values).
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Characterization of compound 4 isolated from Dysidea herbacea – Fractionation of
Dysidea herbacea extract led to the isolation of a single known compound. The compound
appeared as a light yellow glu. 1H NMR (methanol-d4, 500 MHz) δ 7.32 (1H, d, J=2.5 Hz, H-4′),
6.43 (1H, d, J=2.5 Hz, H-6′);

13

C NMR (methanol-d4, 125.7 MHz) δ 150.3 (C-1), 146.6 (C-1′),

145.1 (C-2′), 141.1 (C-2), 130.1 (C-4′), 126.7 (C-3), 121.3 (C-4), 118.9 (C-5), 116.8 (C-6), 116.3
(C-6′), 112.2 (C-3′), 111.2 (C-5′); ESIMS [M-H]- m/z 668.91 (2), 670.86 (24), 672.89 (74),
674.87 (100), 676.85 (67), 678.88 (22), 680.8 7(2); ESIMS [M+Na]+ m/z 691.92 (3), 694.89
(24), 696.85 (65), 698.85 (100), 700.85 (58), 702.83 (19), 705.13 (3). Through comparison of
spectral data previously reported in the literature, the compound was determined to be the
tetrabrominated diphenyl ether: 2-(3′,5′-dibromo-2′-hydroxyphenoxy)-3,4,5,6-tetrabromophenol
[71-73] (Table 5).
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Table 5 1H and 13C NMR spectral data of compound 2 isolated from Dysidea herbacea.
Position
1
2
3
4
5
6
1′
2′
3′
4′
5′
6′

1

H

7.32 (1H, d, J=2.5)
6.43 (1H, d, J=2.5 )

13

C
150.3
141.1
126.7
121.3
118.9
116.8
146.6
145.1
112.2
130.1
111.2
116.3
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Figure 9 Chemical structure of compound 4; an oxy-polyhalogenated diphenyl ether isolated
from Dysidea herbacea.
OH
Br

Br

OH
O

Br

Br

Br
Br

The structure of the active compound was determined to be 2-(3′,5′-Dibromo-2′hydroxyphenoxy)-3,4,5,6-tetrabromophenol.
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Discussion
The activity-driven isolation of the M. africana extract led to the identification of an
active component, mammea A/AA. Mammea A/AA is a 4-phenylcoumarin that has shown in
vitro anti-proliferative activity on a variety of cancer cells [39, 45, 74, 75], high antioxidant
activity [45], and low cytotoxicity to normal cells [75-77], suggesting that mammea A/AA
possesses unique bioactivities worth further investigation. The compound has also been found to
inhibit the growth of methicillin resistant Staphylococcus aureus (MRSA), and methicillin
susceptible Staphylococcus aureus (MSSA), as well as Enterococcus faecalis bacteria [39, 42,
43]. The compound mammea A/AA was also previously tested for in vitro susceptibility against
strains of Escherichia coli, Enterobacter cloacae, Serratia marcescens, Pseudomonas
aeruginosa, Acinetobacter spp., as well as Candida albicans and Cryptococcus neoformans.
Mammea A/AB combined with mammea A/AA in the ratio 4:1 was proven to be ineffective as
an antimicrobial against these gram-negative bacteria and fungi demonstrating MICs above 128
µg/ml [42].
Mammea A/AA has previously been studied by a number of research groups in an effort
to evaluate its anti-cancer activity. This compound was found to exhibit cytotoxicity against the
human 9-KB cancer cell [39]. Researchers also found mammea A/AA to exhibit cytotoxic
activities in the SW-480, HT-29, and HCT-116 human colon cancer cell lines at concentrations
comparable to 5-fluorouracil, a drug frequently used for human colon cancer treatment [45]. An
IC50 value of 6.4 µg/ml for mammea A/AA cyclo has been reported for its cytotoxicity against
A2780 ovarian cancer cells [74]. The cytotoxicity of mammea A/AA was assayed using four
cancer cell lines (HeLa, Calo, SW480, and SW620) and the normal peripheral-blood
mononuclear cells. Results proved that mammea A/AA induced an apoptosis-like cell death in all
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tested cancer cell lines, while showing very low cytotoxicity levels in normal peripheral-blood
mononuclear cells [75]. Furthermore, an investigation of the cytotoxicity of mammea A/AA on
normal human lymphocyte cultures, found that mammea A/AA did not show toxicity, and
demonstrated an LC100 of 120.5 µg/ml [76]. Similarly, this compound was found to be non-toxic
at 50 µM [77]. Support for the further development of mammea A/AA and other mammea
coumarins is prevalent among researchers studying this class of compounds, which are thought
to have significant potential as an alternative antimicrobial in the prevention and treatment of
human infections, and applications as a promising candidate for anticancer treatment.
Bioactivity-guided isolation of the P. papyracea extract led to the identification of the
active component, 4,6-Dibromo-2-(4,6-dibromo-2-hydroxyphenol) anisole [53]. This compound
was previously tested for its antimicrobial activity and was found to possess antimicrobial
activity by inhibiting S. aureus and T. mentographytes (MIC100 0.15, 1.56 µg/ml, respectively)
[50]. Furthermore, it has been found to posess antimicroalgal activity against S. costatum and B.
submaria at 0.5 p.p.m. [53]. A compound with a structure later revised to match this compound
was found to inhibit hypoxia-induced HIF-1 activation (IC50=4.3µM), but also reduced the
viability of T47D and MDA-MD-231 breast tumor cells [4].
The fractionation of a M. unguiculata extract led to isolation of a group of polycyclic
guanidine alkaloids. Similar compounds have previously been isolated from the marine sponge
Monanchora pulcha. The known compounds which were idenitfied as being present were
crambescidin 800, fromainmycalin, and ptilomycalin A. An unknown compound was identified
as Monanchocidin F. The first identified monanchocidin compound, monachocidin A was
revealed as exhibiting a number of uncommon features [57]. Recently, the monanchocidins B-E
were revealed which contain the same structural features; the polycyclic moiety previously
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referred to as the “vessel”, the vicinal hemiketal in a substituted morpholinone ring “anchor” and
hydrocarbon “chain”[78]. The monanchocidin group has previously identified as exhibiting
cytotoxicity against a number of human cell lines, including human leukemia THP-1 (IC50 5.1
µM), and human cervix epitheliod carcinoma Hela (IC50 11.8 µM). This compound was also
found to inhibit mouse epidermal JB6 C141 (IC50 12.3 µM) cell lines [57].
Bioactivity-driven isolation of the antimicrobial component of the final extract, D.
herbacea led to the compound 2-(3′,5′-Dibromo-2′-hydroxyphenoxy)-3,4,5,6-tetrabromophenol.
The oxy-polyhalogenated diphenyl ether group of compounds has previously been found to
display inhibitory activity against the bacteria Bacillus subtilis and fungus Cladosporium
cucumerinum [61]. Their range of activities also includes anti-inflammatory properties,
lipoxygenase inhibition, and anticancer activity [79, 80]. The oxy-polyhalogenated diphenyl
ether group has been investigated for the compounds’ ability to inhibit the overexpression of
Mcl-1 in cancerous cells and it was concluded that these compounds may take advantage of a
synergistic or additive effect, where combined compounds exhibit activities greater than a single
isolated oxy-halogenated diphenyl ether [73].
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CHAPTER

3:

CHARACTERIZATION

OF

ANTIMOCROBIAL

ACTIVITY

OF

ISOLATED COMPOUNDS
Minimum Inhibitory Concentration (MIC)
Introduction
Broth microdilution is the most popular method for performing antimicrobial
susceptibility testing in the U.S. One of the reasons for its popularity is that it produces results
comparable to the “gold standard”: the agar dilution method. Furthermore this method is useful
when testing a number of isolates at a number of different concentrations [81]. The protocol for
this method is available in the Clinical and Laboratory Institutes (CLSI) document M7-A8 and
M11-A8 [37, 38]. The lowest concentration of an antibiotic that will inhibit the growth of the
organism being tested is referred to as the minimal inhibitory concentration (MIC). This value is
usually expressed in µg/ml and is useful to clinicians to determine the appropriate antibacterial
agent and dosage to be used to treat a patient [82]. Antibiotic agents are included in assays for a
variety of reasons. An antibiotic known to inhibit the bacterial species being tested must be
included as a quality control. An antibiotic agent that is currently used to treat the bacterial
infection must also be included in the assays in order for researchers to compare the efficacy of
the natural antimicrobial with that of pharmaceutical agents. Finally, antibiotics may be included
in the tests to determine susceptibility of a bacterial species to the antibiotic.
Materials and Methods
The bacterial species included in MIC determination testing were: A. baumanii, Bacillus
subtilis; ATCC 6051, C. jejuni, Escherichia coli 0157 H:7; ATCC 25922, Listeria
monocytogenes; ATCC 23074, K. pneumoniae, P. aeruginosa, Salmonella enterica serovar
thyphimurium; ATCC 19585, Staphylococcus areus; NCTC 8325 and S. pneumoniae. The
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original plant extract and the active compound were dissolved in dimethyl sulfoxide (DMSO) to
produce a stock solution with the concentration of 1 mg/ml. This was further diluted in sterile
distilled water to prepare test solutions with the concentration of 100 µg/ml. MIC evaluations of
aerobic and anaerobic bacteria were determined by the broth microdilution method according to
CLSI guidelines [37, 38]. MIC evaluations of microaerophilic bacteria were determined as
previously described [83]. In brief, bacterial colonies were selected from 24 h cultures,
suspended in sterile distilled water and adjusted to match a 0.5 McFarland standard by measuring
absorbance at 625 nm using an HTS 7000 Bio Assay Reader (Perkin Elmer, Norwalk, CT). The
bacterial cell numbers were adjusted to approximately 1 x 105 colony forming units (CFU)/ml in
CAMHB, BHI broth, or nutrient broth. Plant extracts, isolated active compounds, and antibiotics
(100 µg/ml) were subjected to serial two-fold dilution in a 96-well microtiter plate. Final test
concentrations ranged from .0125 to 16 µg/ml. Assay plates were incubated in appropriate
conditions (aerobic, anaerobic, or microaerophilic) at 37 ºC for 24 h, and growth was assessed by
measuring absorbance at 625 nm using the Bio Assay Reader. MIC’s of antibiotic agents was
interpreted as the lowest concentration of antibiotic agent to cause an 80% or greater reduction of
growth compared to the growth control. The growth control consisted of DMSO diluted in sterile
distilled water (1:9), and broth, but no test samples. A blank containing no bacteria was also
included. Stock solution of antibiotics, erythromycin, carbenicillin, ciprofloxacin, cefoxitin,
fusidic acid, imipenem, levofloxacin, moxifloxacin, rifampicin, tetracycline, and vancomycin
were prepared according to manufacturer’s suggestions. These were diluted to 100 µg/ml in
sterile distilled water and included in the assay. The assays were performed three times and MIC
values were reported as the mean value of each assay.
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Results
Compound 1 isolated from M. africana displayed inhibitory activity on A. baumannii at 2
µg/ml, while the original M. africana extract did not exhibit inhibitory activity on this bacterial
species even at 16 µg/ml. Furthermore, compound 1 inhibited the growth of the bacteria B.
subtilis, C. jejuni, L. monocytogenes, P. aeruginosa, S. aureus, and S. Pneumoniae with MIC 0.5
µg/ml. Compound 1 did not inhibit E. coli O157:H7, K. Pneumoniae, or S. Typhimurium at
concentrations up to 16 µg/ml as displayed in Table 6.
Compound 2 isolated from P. Papyracea displayed inhibitory activity against B. subtilis
at a concentration of 1 µg/ml, C. jejuni at 2 µg/ml, L. monocytogenes at 8 µg/ml, P. aeruginosa
at 4 µg/ml, S. aureus at 1 µg/ml, and S. pneumoniae at 1 µg/ml (Table 7). Compared with the
original extract, the isolated compound displayed a reduced bioactivity, with the isolated
compound displaying MIC’s at levels between 1 and 4-fold higher than the original extract.
Compound 2 did not show inhibition of growth for the bacteria A. baumannii, E. coli 0157:H7,
K. pneumoniae, or S. typhimurium at concentrations up to 16 µg/ml.
The mixture of compounds in the fraction known as compound 3 displayed antimicrobial
activity against S. aureus at 0.25 µg/ml, B. subtilis at 0.5 µg/ml, C. Jejuni, L. monocytogenes, P.
aeruginosa, and S. pneumoniae at 2 µg/ml, and E. coli 0157:H7, K. pneumoniae, and S.
typhimurium at 4 µg/ml (Table 8). This mixture of compounds was found to be an excellent
inhibitor of every species of bacteria included in the experiment. The mixture of compounds
displayed activity comparable to the original extract. MIC’s for the mixture of compounds was
equal to or within 2-fold higher or lower than the MIC of the original extract. Furthermore,
compound 3 was the only one of the 4 compounds which inhibited the bacterial species, E. coli
0157:H7, K. pneumoniae, and S. typhimurium.
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Compound 4, isolated from D. herbacea, displayed inhibitory activity on B. subtilis and
S. pneumoniae at 0.5 µg/ml, C. Jejuni and P. aeuruginosa at 0.25 µg/ml, L. monocytogenes at 2
µg/ml, and S. aureus at 0.125 µg/ml (Table 9). The isolated compound displayed MIC’s at or
below the MIC of the original extract. This compound failed to inhibit the bacterial species A.
baumannii, E. coli, K. pneumoniae, and S. typhimurium at concentrations up to 16 µg/ml.
MIC’s of commonly used antibiotics against the tested bacterial strains were also
included for comparison. Imipinem, a pharmaceutical agent displayed an MIC at 0.125 µg/ml
against A. Baumannii (Table 10). B. subtilis was inhibited by the antibiotic agents ciprofloxacin,
carbenicillin and tetracycline at 0.25 µg/ml, 0.125 µg/ml and 0.5 µg/ml, respectively. C. jejuni
was inhibited by moxifloxacin at 0.125 µg/ml, ciprofloxacin and levofloxacin at 0.25 µg/ml and
erythromycin at 0.5 µg/ml. E. coli was inhibited by the antibiotics moxifloxacin at 0.125 µg/ml,
and ciprofloxacin and levofloxacin at 0.25 µg/ml. However, erythromycin and vancomycin did
not inhibit E.coli bacteria at concentrations up to 16 µ/ml. L. Monocytogenes was inhibited by
erythromycin at 0.25 µg/ml, tetracycline and vancomycin at 0.5 µg/ml and carbenicillin at 8
µg/ml. K. pneumoniae was inhibited by ciprofloxacin at 0.125 µg/ml and at 0.25 µg/ml by
cefoxitin and imipenem. P. aeruginosa was inhibited by carbenicillin at 0.25 µg/ml and
ciprofloxacin and imipenem at 0.125 µg/ml. MIC of the antibiotics ciprofloxacin and imipenem
on S. typhimurium were 0.125 and 1 µg/ml, respectively. S. pneumoniae was inhibited by
ciprofloxacin, levofloxacin, and moxifloxacin at 0.125 µg/ml. Finally, S. aureus was inhibited by
the antibiotic agents fusidic acid and rifampicin at 0.125 µg/ml and carbenicillin and
erythromycin at 0.5 µg.ml.
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Table 6 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains
exerted by Mammea africana plant crude extract and the isolated coumarin mammea A/AA;
compound 1.

* Each value represents the mean of three observations.
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Table 7 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains
exerted by Phyllospongia papyracea plant crude extract and the isolated tetrabrominated
diphenyl ether; compound 2.

* Each value represents the mean of three observations.
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Table 8 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains
exerted by Monanchora unguiculata plant crude extract and the isolated active mixture of
compounds; compound 3.

* Each value represents the mean of three observations.
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Table 9 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains
exerted by Dysidea herbacea plant crude extract and the isolated active compound; compound 4.

* Each value represents the mean of three observations.

Table 10 The minimum inhibitory concentration (µg/ml) on bacterial growth of bacterial strains exerted by commonly used antibiotics.
Antibiotic MIC (µg/ml)*
Erythromycin

Carbenicillin

Ciprofloxacin

Cefoxitin

Fusidic
Acid

Imipenem

Levofloxacin

Moxifloxacin

Rifampicin

Tetracycline

Vancomycin

Metronidazole

-

-

-

-

-

0.125

-

-

-

-

-

-

-

0.25

0.125

-

-

-

-

-

-

0.5

-

-

Campylobacter
Jejuni

0.5

-

0.25

-

-

-

0.25

0.125

-

-

-

-

Escherichia coli
0157 H:7

>16

-

0.125

-

-

-

-

-

4

1

>16

-

Listeria
Monocytogenes

0.25

8

-

-

-

-

-

-

-

0.5

0.5

-

Klebsiella
Pneumoniae

-

-

0.125

0.25

-

0.25

-

-

-

-

-

-

Pseudomonas
Aeruginosa

-

0.25

0.125

-

0.125

-

-

-

-

-

-

Salmonella
Typhimurium

-

-

0.125

-

1

-

-

-

-

-

-

Streptococcus
Pneumoniae

-

-

0.125

-

-

0.125

0.125

-

-

-

-

Staphylococcus
Aureus

0.5

0.5

-

0.125

-

-

-

0.125

-

-

-

Acinetobacter
Baumannii
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Bacillus Subtilis

* Each value represents the mean of three observations.

Discussion
The inclusion of commonly used antibiotics served three purposes. The first is as a
quality control measure, by aiding in the determination that strains are susceptible to antibiotics
that they should be. Second of all, we were able to determine if the specific strains being tested
were resistant to commonly-used antimicrobials. Third, they were useful for comparison of the
activity of our compounds.
The A. baumannii strain used was susceptible to the antibiotic imipenem based on the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints
[84]. A. baumannii has been proven to be multi-drug resistant and to have unpredictable
susceptibility patterns [85]. Therefore, replacements to conventional therapies are always
needed. Compounds 1 and 3 show a high level of inhibitory activity on this bacterial species and
could be considered for further study.
B. subtilis was considered susceptible to the antibiotic ciprofloxacin based on EUCAST
breakpoints. All four compounds inhibited this species of bacteria with an MIC of 1 µg/ml or
lower, and compounds 1, 3, and 4 all inhibited at a level equivalent to the commonly-used
antibiotic tetracycline (MIC = 0.5 µg/ml)
Based on clinical breakpoints, the C. jejuni species used was susceptible to the
antibiotics erythromycin and ciprofloxacin. While all four compounds displayed inhibitory
activity of equal to or less than 2 µg/ml, compound 4 was the most effective, inhibiting at 0.25
µg/ml, equivalent to the commonly used antibiotics ciprofloxacin and levofloxacin.
The strain of E. coli 0157H7 tested was susceptible to the commonly-used antibiotic
ciprofloxacin, but was not inhibited by erythromycin or vancomycin even at 16 µg/ml. Of the
four compounds tested, only compound 3 was able to inhibit the growth of the bacteria.
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Compound 3 inhibited the strain of E. coli at 4 µg/ml, but it is also important to note that the
original M. unguiculata extract displayed equivalent activity. Both the compound mixture and
the extract displayed activity at the level of the antibiotic rifampicin.
The L. monocytogenes strain tested displayed susceptibility to the antibiotic
erythromycin based on EUCAST breakpoints. Compound 1 was found to have the strongest
inhibitory activity of the isolated compounds at MIC of 0.5 µg/ml. This is equivalent to two
commonly used antibiotics, tetracycline and vancomycin. Compounds 3 and 4 displayed
inhibitory activity at 2 µg/ml, proving they too have potential applicability as replacement
antimicrobials for this common pathogen.
K. pneumoniae was susceptible to the commonly used antibiotics ciprofloxacin and
imipenem in this test. Compound 3 was the only isolated product to inhibit this species of
bacteria. The MIC of 4 µg/ml was equivalent to the MIC of the M. unguiculata extract, which
leads to the belief that other active compounds exist within the extract and together create an
additive effect.
P. aeruginosa was susceptible to the commonly used antibiotics ciprofloxacin and
imipenem. Compound 4 showed the most prominent activity against P. aeruginosa, with an MIC
of 0.25 µg/ml; equivalent to the antibiotic carbenicillin. The MIC of compound 1 was 0.5 µg/ml,
proving either compound could be a potential alternative for current pharmaceuticals.
S. typhimurium was susceptible to the two antibiotics commonly used for its treatment;
ciprofloxacin and imipenem. Only compound 3 displayed inhibitory activity on this species of
bacteria (MIC = 4 µg/ml). Furthermore, the MIC of the isolated mixture of compounds was
higher than the MIC for the M. unguiculata extract.
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S. pneumoniae was susceptible to ciprofloxacin, levofloxacin, and moxifloacin.
Compounds 1 and 4 displayed a high level of activity with MICs of 0.5 µg/ml.
S. aureus was proven to be susceptible to antibiotics erythromycin, fusidic acid, and
rifampicing based on EUCAST breakpoints. All of the isolated products tested inhibited this
strain of bacteria at or below 1 µg/ml. Compound 4 displayed the greated activity, with an MIC
of only 0.125 µg/ml, which is equivalent to or greater than all the antibiotics included.
In conclusion, the four compounds isolated displayed broad-spectrum antimicrobial
activity. All of the compounds were successful at inhibited both gram-positive and gramnegative bacteria. The gram-negative bacteria posed a greater challenge to the compounds, as
compounds 1, 2, and 4 failed to inhibit the same three gram negative bacteria; E. coli 0157: H7,
K. pneumoniae, and S. typhimurium. These three bacterial species are all part of the same family,
known as enterobaceriaceae. Furthermore, compounds 2 and 4 also failed to inhibit gram
negative A. baumannii at concentrations up to 16 µg/ml. The isolated mixture of compound 3
successfully inhibited the gram-positive bacteria as well as these more challenging gram negative
bacteria, proving superior antimicrobial ability. Unfortunately, for the most part, fractionation of
M. unguiculata did not lead to improved activity over the original extract. Further testing would
likely lead to other active compounds in the M. unguiculata extract. Combining a number of
isolated compounds would likely produce a stronger effect than the original extract, however, the
low MIC values obtained prove that M. unguiculata extract may have potential antimicrobial use
even without fractionation.
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Minimum Bactericidal Concentration (MBC)
Introduction
The MIC test proves the inhibitory activity of the sample tested; however, it does not
indicate the action of the antibacterial agent. Researchers often improve the MIC testing by
testing to see if growth of the microorganism will begin again following the removal of the
antibacterial agent. Therefore, it is important to follow-up this test by determining the minimal
bactericidal concentration (MBC) of the sample. MBC is the lowest concentration of an
antibiotic to kill 99.9% of a bacterial inoculum [82]. Researchers use these two tests to determine
the mode of action of the antimicrobial compound, being either bacteriostatic or bactericidal.
Materials and Methods
Following the broth microdilution test for MIC, 20 µl of suspension was removed from
each microtitre plate well showing no growth, and transferred to a new well containing 240 µl of
sterilized broth. Following a 24 hour incubation period at 37 ºC in appropriate conditions, the
results were obtained by measuring absorbance at 625 nm. The MBC was determined as the
lowest concentration of antibacterial agent in the original MIC test sample to cause a onethousand fold reduction in bacterial growth compared with the growth control (99.9% killing).
Results
The effect of compound 1 on the bacterial species A. baumannii is considered
bactericidal as the MIC and MBC are equal. For the remaining bacterial species inhibited by
compound 1, a 1 to four-fold increase in concentration was required to obtain a bactericidal
effect; with the exception of B. subtilis with an MBC 32-fold greater than the recorded MIC
(Table 11).
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Similarly, a bactericidal effect was seen at the MIC of compound 2 on the bacterial
species C. jejuni and L. monocytogenes. By increasing the concentration by 1 to 4fold more than
the MIC value, a bactericidal effect could be produced for the other bacterial species (Table 12).
Against B. subtilis, the bacteriocidal effect was not evident even up to concentrations of 16
µg/ml. In most cases, the original P. papyracea extract exhibited stronger bactericidal effect than
the isolated compound 2.
The mixture of compounds present in compound 3 displayed strong bactericidal activity
with MBCs equal to the MICs for A. baumannii, C. jejuni, E. coli 0157:H7, K. pneumoniae, P.
aeruginosa, and S. pneumoniae (Table 13). MBCs were slightly increased from the MICs for L.
monocytogenes, S. typhimurium, and S. aureus. Finally, 16 µg/ml of the compound mixture was
required to obtain a bactericidal effect on the bacterial species B. subtilis, although the MIC was
0.5 µg/ml.
Finally, compound 4 exerted bactericidal activity on S. pneumoniae at the MIC of 0.5
µg/ml. A bactericidal effect could be seen at 2-8x the MIC for all other bacterial species involved
(Table 14).
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Table 11 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial
strains exerted by Mammea africana plant crude extract and the isolated coumarin mammea
A/AA; compound 1.
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Table 12 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial
strains exerted by Phyllospongia papyracea plant crude extract and the isolated tetrabrominated
diphenyl ether; compound 2.
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Table 13 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial
strains exerted by Monanchora unguiculata plant crude extract and the isolated active mixture
of compounds; compound 3.
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Table 14 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial
strains exerted by Dysidea herbacea plant crude extract and the isolated active compound;
compound 4.

* Each value represents the mean of three observations.

Table 15 The minimum bactericidal concentration (MBC) on bacterial growth of bacterial strains exerted by commonly used antibiotics.
Antibiotic MBC (µg/ml)*
Erythromycin

Carbenicillin

Cefoxitin

Ciprofloxacin

Imipenem

Fusidic
Acid

Levofloxacin

Moxifloxacin

Rifampicin

Tetracycline

Vancomycin

Metronidazole

-

-

-

-

0.25

-

-

-

-

-

-

-

-

4

-

0.5

-

-

-

-

-

4

-

-

Campylobacter
Jejuni

0.5

-

-

0.5

-

-

0.25

0.125

-

-

-

-

Escherichia coli
0157 H:7

>16

-

-

0.125

-

-

-

-

8

8

>16

-

Klebsiella
Pneumoniae

-

-

16

0.125

0.25

-

-

-

-

-

-

-

Listeria
Monocytogenes

0.5

16

-

-

-

-

-

-

-

2

1

-

-

1

-

1

0.25

-

-

-

-

-

-

-

Salmonella
Typhimurium

-

-

-

0.125

4

-

-

-

-

-

-

-

Staphyloccus
Aureus

0.5

2

-

-

-

0.5

-

-

0.125

-

0.5

-

Streptococcus
Pneumoniae

-

-

-

0.125

-

-

0.125

0.125

-

-

-

-

Acinetobacter
Baumannii
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Bacillus Subtilis

Pseudomonas
Aeruginosa

* Each value represents the mean of three observations.

Discussion
In most cases, the MIC represents a bacteriostatic activity. By increasing the
concentration above the MIC, a bactericidal activity can be produced. Although breakpoint
values only exist for MIC values, this trend is also true of the commonly used antibiotic agents,
of which most required an increased concentration for their activity to be considered bactericidal.
Compounds 1, 2, and 3 could only produce a bactericidal effect on B. subtilis bacteria at
high concentrations (MBC 16 µg/ml or above). Compound 4 displayed a far superior bactericidal
activity on this bacterial species, with a low MBC of 4 µg/ml, making a good candidate for
further drug development.
The mixture of compounds present in compound 3 displayed significant bactericidal
activity against all the bacterial species included except B. subtilis. It can be concluded that this
mixture of compounds has strong broad-spectrum bactericidal activity, which deserves further
investigation.
Similar to the results of MIC testing, MBC testing showed decreased MBC values when
the isolated product was compared with the original extract, only in the cases of compounds 1
and 4. Compounds 2 and 3 often showed a higher MBC value than the original extract which
further solidifies the hypothesis that some bioactive compounds were lost during fractionation. A
second possible explanation is that the isolated compounds themselves degrade over time, losing
activity, while the original extract is significantly more stable, and does not lose activity during
storage.
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CHAPTER 4: APPLICABILITY OF ISOLATED COMPOUNDS
Introduction
Stability testing evaluates the effect of environmental factors on the efficacy of a drug
substance [86]. Stability testing to ensure product quality, safety, and efficacy are required prior
to the approval of any pharmaceutical product. At the developmental stage, stability studies
provide information required to determine shelf-life, packaging, and storage conditions [86]. The
influence of environmental factors on the activity of the product being developed must be
determined as temperature, humidity, and light are known to have a detrimental effect on some
active compounds. In packaged foods, growth and survival of common spoilage and pathogenic
microorganisms such as L. monocytogenes, E. coli 0157:H7, S. enterica serovar typhimurium, S.
aureus, and C. Jejuni, are affected by a variety of intrinsic factors, such as pH and oxygen
presence, as well as extrinsic factors of storage conditions, including temperature, time, and
relative humidity [34]. The temperature of cooking may affect the antimicrobial compounds of
natural products in foodborne pathogens. Therefore, heat treatment is required to determine if the
antimicrobial compound has potential use as a commercial antimicrobial which could be applied
to food products [87]. Stress testing of compounds often requires treatment with high heat, which
serves not only the purpose of addressing the compound’s ability to withstand temperature
associated with food storage, processing, cooking, or sterilization, but also as a method of
accelerated aging. In this way, a compound that can withstand heat treatment at a high
temperature is considered more likely to remain stable over long periods of storage.
Foods have various pH levels, usually ranging from pH 3 for foods such as cheese and
pasta up to pH 10 for foods such as spinach and broccoli. If an antimicrobial agent becomes
ineffective at a specific pH level, this will limit its potential application as a food preservative.
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The role of pH level is important to consider as it has an effect on the growth rate of microbes, as
well as the interaction of antimicrobial agent and microbial growth; affecting the MIC of the
agent. The optimal pH for bacterial growth is usually between ph 6-8, however, even foods with
pH levels at the far ends of the spectrum are subject to spoilage and/or pathogenic bacteria.
Antimicrobial agents also have a specific pH at which they display optimal activity. Food
preservatives have known optimal pH levels which are usually reflects the active moiety of the
molecule and determines the application that the specific agent may be used for.
Finally, the shelf-stability of a potential pharmaceutical agent must be considered
during the development stage of any drug. The optimal conditions of storage must be determined
to facilitate proper packaging and storage instructions, as well as to estimate the product’s shelflife. Most products will remain stable longer if stored at lower temperatures, however, it is most
convenient to store pharmaceutical products at room temperature. Exposure of the product to
light is also important to consider as light is known to cause compound degradation, which will
significantly impact the activity of a natural antimicrobial. Intermediate length testing should
cover a minimum of six months duration, however, it is considered unnecessary to continue
testing if a significant change in efficacy is seen in the first three months [88]. In general, a loss
of activity up to 85% can lead to failure in therapy, and is considered significant loss of activity
[86].
Materials and Methods
Thermal Stress Testing - Isolated compounds (100 µg/ml in water) were heated to 37ºC,
50ºC, 80ºC, 100ºC, and 121ºC for 15 minutes using a Fisher Scientific Isotemp hot plate.
Samples were removed to ice for 10 minutes for immediate cooling. Following heat treatment,
the level of bioactivity of the compounds was assessed via broth microdilution method as
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previously described [89]. Bacterial colonies of B. subtilis were selected from 24 h cultures,
suspended in sterile distilled water and adjusted to match a 0.5 McFarland standard by measuring
absorbance at 625 nm using an HTS 7000 Bio Assay Reader (Perkin Elmer, Norwalk, CT). The
bacterial cell numbers were adjusted to approximately 1 x 105 colony forming units (CFU)/ml.
Isolated active compounds stored in the freezer and compounds which had undergone heat
treatment were subjected to serial two-fold dilution in a 96-well microtiter plate with final test
concentrations ranging from .0125 to 16 µg/ml. Assay plates were incubated at 37 ºC for 24 h,
and growth was assessed by measuring absorbance at 625 nm using the Bio Assay Reader.
MIC’s of antibiotic agents was interpreted as the lowest concentration of antibiotic agent to
cause an 80% or greater reduction of growth compared to the growth control. The growth control
consisted of DMSO diluted in sterile distilled water (1:9), and broth, but no test samples. A blank
containing no bacteria was also included. The assays were performed three times and MIC
values were reported as the mean value of each assay.
Effect of pH Treatment - Buffers were prepared at pH 3, 4, 5, 6, 8, 9, and 10. Stock
solutions of active compounds (1 mg/ml in DMSO) were evaporated under the fume hood
overnight. Buffers or sterile distilled water (pH 7) were added to dried samples to achieve
samples with a final concentration of 100 µg/ml. Samples were mixed using a vortex mixer. The
level of bioactivity of the compounds was assessed via broth microdilution method as previously
described. Bacterial colonies of B. subtilis were selected from 24 h cultures, suspended in sterile
distilled water and adjusted to match a 0.5 McFarland standard by measuring absorbance at 625
nm using an HTS 7000 Bio Assay Reader (Perkin Elmer, Norwalk, CT). The bacterial cell
numbers were adjusted to approximately 1 x 105 colony forming units (CFU)/ml. Isolated active
compounds treated with buffers at various pH levels were subjected to serial two-fold dilution in
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a 96-well microtiter plate with final test concentrations ranging from .0125 to 16 µg/ml. Assay
plates were incubated at 37 ºC for 24 h, and growth was assessed by measuring absorbance at
625 nm using the Bio Assay Reader. MIC’s of antibiotic agents was interpreted as the lowest
concentration of antibiotic agent to cause an 80% or greater reduction of growth compared to the
growth control. A set of growth controls was included in this assay in order to serve as a control
for variations in growth of B. subtilis bacteria based on the inclusion of the buffers in the
concentration range of .0125 to 16 µg/ml in the growth medium [90]. A blank containing no
bacteria was also included.
Storage Conditions - Samples of isolated active compounds 1-4 (100 µg/ml in sterile
distilled water) were placed in various storage conditions. The conditions chosen for testing
were: -20ºC (freezer), 4ºC (fridge), room temperature without light exposure, and room
temperature with light exposure. Samples were removed from storage at one month intervals and
bioactivity was assessed by broth microdilution as previously described. Bacterial colonies of B.
subtilis were selected from 24 h cultures, suspended in sterile distilled water and adjusted to
match a 0.5 McFarland standard by measuring absorbance at 625 nm using an HTS 7000 Bio
Assay Reader (Perkin Elmer, Norwalk, CT). The bacterial cell numbers were adjusted to
approximately 1 x 105 colony forming units (CFU)/ml. Isolated active compounds treated with
varying storage environments were subjected to serial two-fold dilution in a 96-well microtiter
plate with final test concentrations ranging from .0125 to 16 µg/ml. Assay plates were incubated
at 37 ºC for 24 h, and growth was assessed by measuring absorbance at 625 nm using the Bio
Assay Reader. MIC’s of antibiotic agents was interpreted as the lowest concentration of
antibiotic agent to cause an 80% or greater reduction of growth compared to the growth control.
The growth control consisted of DMSO diluted in sterile distilled water (1:9), and broth, but no
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test samples. A blank containing no bacteria was also included. They were tested for a period of
6 months.
Results
Thermal Stress Testing - Compound 1 did not show any loss in activity following heat
treatment at 50 ˚C. Heat treatment at 80 ˚C caused a slight loss in activity which became more
pronounced with treatment above 100 ˚C. Although this compound proved to be susceptible to
heat treatment, even following treatment at 121 ˚C for 15 minutes, the compound was still able to
inhibit the B. subtilis bacteria at a low MIC of 2 µg/ml (Figure 10).
Thermal stability testing proved that compound 2 was the most susceptible to heat
treatment. It had significant loss of activity against B. subtilis even when heated only to body
temperature 37 ˚C. Following heat treatment of 80 ˚C for 15 minutes, the compound did not
inhibit the growth of B. subtilis bacteria even at the highest tested concentration of 16 µg/ml.
The mixture of compounds present in compound 3 was determined to be highly heatstable. Following heat treatment at 121 ˚C, the antimicrobial activity was only slightly decreased,
producing a low MIC of 1 µg/ml.
Compound 4 maintained its activity following heat treatment of 100 ˚C (MIC = 0.5
µg/ml). It showed decreased activity following heat treatment at 121 ˚C displaying an MIC
which increased to 4 µg/ml.
Effect of pH Treatment - None of the pH buffers on their own significantly inhibited the
growth of the B. Subtilis bacteria, although, as expected, the highest level of bacterial growth
was recorded when buffers at pH of 6 and 7 were included. This proves that even small amounts
of basic or alkaline buffer will decrease the growth rate of the B. subtilis bacteria. Compound 1
did not show any inhibition on the B. Subtilis even up to a concentration of 16 µg/ml. Compound
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2 showed inhibition at the MIC level of 1 µg/ml with pH buffer 10 only. With pH buffer 9, the
bacteria was inhibited at 4 µg/ml. Compound 3 showed inhibition at 16 ppm when buffers at pH
3, 5, and 7 were included. Finally, compound 4 showed inhibition at 1 µg/ml when buffers at ph
9 and 10 were included and at 4 µg/ml with buffer at pH 8.
Storage Conditions - Compound 2 showed significant loss of activity following storage
at -20 ˚C by 2 months time. By 6 months, compound 2 displayed an MIC of 16 µg/ml, compared
to an MIC of 1 µg/ml at Day 1. Compound 1 retained its bioactivity throughout 4 months of
storage at -20 ˚C, however, at month 5 the compound displayed a higher MIC of 8 µg/ml.
Compounds 3 and 4 exhibited strong antimicrobial activity against B. subtils following 6 months
of storage at -20 ˚C. At the 6 month time-point both compounds exhibited an MIC of only 2
µg/ml (Figure 11).
Fridge storage at 4 ˚C produced similar results to those obtained following storage in the
freezer (Figure 12). Compound 2 showed significant instability and at month 6 did not inhibit B.
subtilis even at the highest tested concentration of 16 µg/ml. Compound 1 remained stable until 4
months, but showed a significant reduction in activity at month 5 and 6. Compounds 3 and 4
remained relatively stable throughout the test period.
Compound 2 appeared to be the least stable of the compounds when stored at room
temperature without light exposure. It exhibited an MIC of 8 µg/ml against B. subtilis at month 2
and 3, which increased to 16 µg/ml by month 4. At 6 months time the compound no longer
displayed bioactivity against the bacteria even at the highest tested concentration of 16 µg/ml.
Compound 1 was the second least stable of the compounds stored in this environment. At month
5, compound 1 displayed an MIC of 8 µg/ml against B. subtilis, which rose to 16 µg/ml at month
6. Compound 3 was able to retain its bioactivity following 6 months of storage at room
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temperature without exposure to light. Following the 6 month storage period, the mixture of
compounds exhibited the low MIC of 2 µg/ml (Figure 13). Finally, compound 4 showed it is
susceptible to higher storage temperatures as it displayed an increased MIC of 4 µg/ml at month
5 and 6.
As displayed in Figure 14, the activity of the isolated compounds was decreased
following storage at room temperature with light exposure. Compound 2 displayed an MIC of 16
µg/ml against B. subtilis following only 4 months of storage. Compound 1 had lost its inhibitory
activity against B. subtilis at all tested concentrations by 6 months time. Compound 3 showed the
most stability, exhibiting an MIC of 4 µg/ml following the test period. Finally, compound 4
displayed an MIC of 8 µg/ml following 6 months of storage at room temperature with exposure
to light.
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Figure 10 Minimum inhibitory concentration (MIC) of heat treated compounds against B.
subtilis bacteria.
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Figure 11 Minimum inhibitory concentration (MIC) of compounds stored at -20 ˚C against B.
subtilis bacteria.
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Figure 12 Minimum inhibitory concentration (MIC) of compounds stored at 4 ˚C against B.
subtilis bacteria.
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Figure 13 Minimum inhibitory concentration (MIC) of compounds stored at room temperature
without light exposure against B. subtilis bacteria.
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Figure 14 Minimum inhibitory concentration (MIC) of compounds stored at room temperature
with light exposure against B. subtilis bacteria.
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Discussion
Thermal Stress Testing - Compounds isolated from plant and marine organisms were
subjected to various levels of heat treatment. Only compound 2 showed a significantly decreased
activity level at human body temperature of 37 ˚C. This compound may not be stable enough to
be used as a pharmaceutical agent, as it may not provide the desired effect in such circumstances.
Furthermore, compound 2 was not able to inhibit the B. subtilis bacteria following heat treatment
at 80 ˚C even at the highest tested concentration of 16 µg/ml. Thermal treatment of antimicrobial
agents which resulted in a reduction of antimicrobial activity suggests compound degradation
[91]. The potential applications of compound 2 are limited as the results of the thermal stress test
lead to the fact that compound 2 is unlikely to hold up to long-term stability tested even at lower
temperatures.
The remaining compounds maintained a high level of activity following heat treatment
at temperatures up to 121 ˚C. This proves that these compounds may have potential application
as pharmaceutical agents, or food preservatives. The concentration used may need to be
increased to compensate for the 8-fold reduction of activity of compound 4 at 121 ˚C. The results
also lead to the hypothesis that compounds 2 and 3 are the most likely to remain active following
more long-term shelf stability testing.
Effect of pH Treatment - The compounds were originally dissolved in DMSO to produce
the stock solution which was stored in the freezer. Stock solutions were dried under the fume
hood overnight, so that the compounds were able to be rehydrated in buffer and access the effect
of the varying pH level on the efficacy of the antimicrobial agent. Unfortunately, dissolving the
compounds directly in buffer was not possible. The results prove that the compounds had
significant loss of activity following the preparation of the samples. This is apparent by the fact
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that none of the compounds performed as expected even when only water was added to the
CAMHB broth. There are two possible explanations for the results that were obtained. The first
explanation is that the active compounds were volatile and lost activity during the drying of the
stock solution. A second possibility is that the active compounds bound to the vial when the
DMSO was evaporated, and when buffer was added, the active compound did not become
incorporated into the solution, even with vortex mixing. Compounds 2 and 4 did show inhibitory
activity at the low concentration of 1 µg/ml at a few specific pH levels, however, there is not
sufficient data to support any findings on the effect of pH on the isolated active compounds. It is
most probable that buffers of pH 9 and 10 were the most successful at dissolving compounds 2
and 4. Although DMSO and distilled water have similar pH levels, DMSO is an aprotic solvent
while water represents a protic solvent and has a higher polarity. These differences are likely
responsible for the unexpected results.
Storage Conditions - As expected, all the compounds were found to be susceptible to
variations in storage conditions. Compound 1 displayed an increased stability when stored at
fridge or freezer temperature. Furthermore, exposure to light had an effect on the bioactivity of
the compound. The applicability of this compound is limited as it is not shelf-stable for an
extended period of time.
Compound 2 was the least stable of the compounds examined. In all storage conditions
the compound displayed significant loss of bioactivity against B. subtilis. Only when stored at 20 ˚C did the compound show any inhibitory activity at month 6 (MIC of 16 µg/ml). This
compound has shown instability in all tests, and would not be chosen for further development for
this reason.
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The mixture of compounds present in compound 3 retained activity following 6 months
of storage in all of the tested environments. This compound is the most likely to be shelf-stable
for an extended period of time.
Compound 4 was the second most stable of all the compounds tested. It retained
inhibitory activity in all tested environments. This compound was susceptible to light, so opaque
packaging would be recommended to increase the shelf-life of this product.
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CHAPTER 5: CYTOTOXICITY OF ISOLATED COMPOUNDS
Introduction
Plants have been eaten and used in traditional medicine for centuries. This leads many to
believe that all compounds derived from natural sources are safe for human consumption.
However, an isolated active compound requires testing to ensure it is safe in its purified form,
and at the level required to inhibit the bacterial growth. Plant research is currently separated into
ethnopharmacology (ex. medicinal herbs) and toxicology (ex. poisonous plants). Both types of
research have led to the production of drugs and lead compounds [34]. Compounds are often
tested using an in vitro cell culture system and cytotoxicity is determined by the effect of the
compound on the cell growth rate [92]. MTS assay represents a well established measurement
system for cytotoxicity. The assay relies on the conversion of a tetrazolium salt into a coloured
formazan product by mitochondrial activity of viable cells. The amount of living cells in the
culture is directly proportional to the amount of formazan produced and is measured at 492 nm
[93]. The assay is known to produce precise results in a timely manner [94].
Materials and Methods
To fulfill this aim, the cytotoxicity of isolated active compounds was determined by
MTS assay using mouse embryonic fibroblast (MEF) cell line, NIH 3T3 obtained from ATCC.
MTS assay was conducted as previously described [95]. Active compounds were dissolved in
DMSO to prepare a stock solution with a concentration of 1 mg/ml. The stock solution was
diluted in sterile distilled water to obtain samples with a concentration of 250 µg/ml. The NIH
3T3 cells (5 x 103) were seeded in a 96-well culture plate and after overnight incubation the
medium was removed and replaced with a fresh medium containing isolated active compounds at
50 µ/ml, 25 µg/ml. Controls were included that did not contain any test substance (1:3 water:
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DMSO or 1:7 water: DMSO). After 72 h of incubation, 20 µl of CellTiter 96 AQueous One
Solution Reagent (Promega, Madison, WI) was added to each well. After 2 h incubation at 37 °C
in a humidified, 5 % CO2 atmosphere, the absorbance at 485 nm was recorded on an ELx800
plate reader (Bio-Tek, Winooski, VT). The untreated control of every experiment was defined as
100% proliferation and the values of the antimicrobial-treated cultures were calculated in relation
to the control. Each variant of the experiment was performed in octuplet.
Results
Cell proliferation studies of the isolated active compounds showed varying degrees of
cytotoxicity using the NIH 3T3 MEF cell line. At a concentration of 25 µg/ml, all compounds
exhibited significant cytotoxicity (Table 16). Compounds 1 and 4 displayed 40.5 and 41.6%
proliferation, respectively. The MEF cell line was further diminished by treatment with
compounds 2 and 3 at 25 µg/ml, resulting in only 9.8% and 5.4% cell proliferation, respectively.
When the concentration of isolated active compounds was increased to 50 µg/ml, the
results were more pronounced. The MEF cell line treated with compounds at 50 µg/ml resulted
in almost complete obliteration of cell viability. Cell proliferation was between 0.32% and 3.9%
following treatment with isolated active compounds 1-4 at a concentration of 50 µg/ml (Table
17).
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Figure 15 MTS assay of NIH 3T3 cell proliferation caused by isolated active compounds at a
concentration of 25 µg/ml.
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Table 16 MTS assay of NIH 3T3 cell proliferation caused by isolated active compounds at a
concentration of 50 µg/ml.
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Discussion
All isolated compounds were found to be cytotoxic to the mouse embryonic fibroblast
(MEF) cell line, NIH 3T3. Although this has important implications in the applicability of the
compounds and their further development, it is not uncommon for the current pharmaceutical
antibiotics to be cytotoxic to normal human cells. Researchers tested the cytotoxicity of common
antibiotics ciprofloxacin, moxifloxacin, erythromycin against primary human osteoblasts. The
commonly used antibiotics were found to display cytotoxicity, however higher concentrations
were tested (400 µg/ml) [96]. Researchers often determine the specific mechanism by which an
agent exerts cytotoxicity. After isolating the cause of the cytotoxicity, it is possible to modify the
structure of the compound to remove its cytotoxic effect, while keeping its desirable
antimicrobial activity. This process of molecular modification is a step in the drug development
process which is often carried out when a lead compound with exceptional bioactivity is
discovered to exhibit cytotoxicity [97].

91
CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS
The ongoing development of resistance of pathogenic bacteria to antibiotics represents a
major threat to public health. The issue is exacerbated by the fact that new drugs rarely succeed
in being fully developed and made available to consumers [98]. Natural products have seemingly
endless chemical diversity and are central to current pharmaceutical development [98]. The
primary aim of this project was to identify and characterize components of plant and marine
extracts with inhibitory activity against those bacterial species which are considered high priority
due to antimicrobial resistance and high incidence of occurrence.
In this study, extracts of plant and marine organisms were screened for antimicrobial
activity against a number of high priority bacterial pathogens. Screening led to the identification
of four extracts with superior, broad-spectrum, antimicrobial activity. The extracts chosen were
from M. africana, P. papyracea, M. unguiculata, and D. herbacea; a plant organism and three
marine sponges. Bioassay-guided fractionation of the extracts led to the isolation of the active
component in each extract. Extracts from M. africana, P. papyracea, and D. herbacea each led
to the isolation and identification of a single, previously known compound; compounds 1, 2, and
4, respectively. The fractionation of the marine sponge M. unguiculata led to the isolation of a
mixture of compounds, containing one previously unknown compound, monanchocidin F. All of
the isolated active compounds displayed antimicrobial activity considered potentially useful for
pharmaceutical development, ie. MIC’s in the range of 0.02-10 µg/ml [98]. While all the
compounds displayed antimicrobial activity on a variety of gram-positive and gram-negative
bacteria, only the mixture of compounds in compound 3 was able to inhibit the growth of three
species of gram-negative enterobaceriaceae E. coli 0157h7, K. pneumoniae, and S. typhimurium.
After examining the ability of the isolated compounds to retain their antimicrobial effect
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following thermal stress, and storage in various environments, it was found that compounds 3
and 4 were very stable, compound 1 was intermediate, and compound 2 was highly unstable.
Finally, MTS assay proved that all the compounds were cytotoxic to the mouse embryonic cell
line NIH 3T3.
In some cases, the extracts and isolated active compounds displayed similar levels of
inhibitory activity against bacterial species. The loss of bioactivity is a common setback involved
in isolation of bioactive components of extracts. Compounds 2 and 3 displayed inhibitory
activity similar to the original extract of P. papyracea and M. unguiculata, respectively. Stability
testing led to the conclusion that compound 2 is highly instable in nature. It is most likely that
the degradation of compound 2 led to its decreased antimicrobial activity when compared with
the original extract. For this reason, it would not be advisable to continue development of
compound 2 as a natural antimicrobial. In the case of the mixture of compounds in compound 3,
this mixture of compounds performed very well in stability studies and withstood environmental
factors of degradation. This leads to the conclusions that the M. unguiculata extract may contain
other antimicrobial components that were passed over during fractionation. It is likely that the
mixture of compounds in compound 3, although highly active on their own, may work
synergistically with other compounds in the extract. As compound 3 includes a previously
undiscovered compound, which has been shown to be possess strong antimicrobial activity and
stability, future directions for this work should focus heavily on the M. unguiculata extract. A
small sample of extract was obtained for the purpose of this work. For future work, a larger
sample of M. unguiculata may be obtained. This sample may be extracted and fractionated in a
similar fashion to identify and isolate each active compound within the extract. Finally, the
compounds may be combined in varying ratios to increase their antimicrobial activity. Although
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compound 3 exhibited inhibitory activity on all of the bacterial species included in this study,
further development should focus on its activity against the gram-negative enterobaceriaceae, E.
coli 0157: H7, K. pneumoniae, and S. typhimurium. Further research should focus on elucidating
the mechanism responsible for the antimicrobial activity of these compounds, as well as the
mode of action responsible for their cytotoxicity. Molecular modification may be employed to
further develop the lead compound.
Future work should also focus on the development of compound 1 as a replacement for
the pharmaceutical agents used to control the bacterial species A. baumannii, and L.
monocytogenes. Compound 1 displayed high antimicrobial activity against these two high
priority pathogens which has not been described previously.
Compound 4 deserves further development as a natural antimicrobial as well. It could be
developed as a replacement for currently used antibiotics for B. subtilis, C. Jejuni, P. aeruginosa,
S. aureus, and S. pneumoniae. Compound 4 has potential as an antibmicrobial as it was highly
active against a broad spectrum of bacterial species, it was a lead compound, displaying lower
MIC’s than the original extract, and it was found to be highly stable to stress and environmental
factors. Future research should focus on the mechanism of action of the oxy-polyhalogenated
diphenyl ether isolated from Dysidea herbacea as well as the mechanisms responsible for it’s
cytotoxicity against the MEF cell line. Chemical modification of this compound could lead to
pharmaceutical development.
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Antibiotic agents have been found to have a limited lifespan due to the ability of
microrganisms to develop antimicrobial resistance. In this study a number extracts of plant and
marine organisms were evaluated for their antimicrobial activity against a number of high
priority pathogens. Bioassay-guided fractionation of four extracts led to the identification of
compounds with inhibitory activity; including one previously unknown compound. Compounds
were evaluated through a variety of techniques including broth microdilution assay to determine
each compound’s MIC and MBC. The majority of the compounds showed antimicrobial activity
equal to, if not better than, the commonly used antimicrobial drugs. The ability of compounds to
withstand environmental stress and storage were explored with only one compound showing
significant instability. Finally MTS assay showed that cell proliferation was decreased when
mouse embryonic fibroblast cells, NIH 3T3 were treated with the compounds, proving they are
cytotoxic to varying degrees.
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